Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 16, 2013

View Archived Issues

HE-400 affects multiple pathways linked to IBS

Novel FabI inhibitors active against resistant S. aureus

Flatley Discovery Lab nominates drug candidate for cystic fibrosis

Starpharma's dendrimer-enhanced oxaliplatin shows reduced neurotoxicity in mouse model

Microbiotix describes activity of antibacterials with dual mechanism of action

Efficacy seen with PEG-rHuPH20 plus gemcitabine in pancreatic cancer

Preclinical studies with GLV-1h68 in sarcoma lead to phase I clinical trial

Hepatitis A virus cellular receptor has prognostic significance in breast cancer

German and Swiss team presents novel carbohydrate-based vaccines

Roche discloses new agents for hepatitis B virus infection

Scientists at Bayer Healthcare patent novel Mnk1 inhibitors

Daiichi Sankyo synthesizes new EP2 inhibitors

Novel gp41 peptide mimetics for HIV infection

Amarantus BioScience reports analytical performance data for the LymPro Test

DiaGenic provides update on two diagnostic tests for AD

University Health Network plans phase I safety and pharmacokinetic study of CFI-400945

Berg and Icahn School of Medicine form pharmaceutical and diagnostic R&D partnership

QRxPharma expands MoxDuo agreement with Aspen Pharmacare

Medical Developments submits MAA in Europe for penthrox

Symphogen and OMT collaborate to develop novel therapeutic candidates

OncoCyte enters collaboration with Wistar Institute to develop cancer diagnostics

KineMed and Amgen enter agreement to develop kinetic biomarkers

Enrollment completed in phase II Arikace study in NTM lung disease

Reversal of anticoagulation effect of factor Xa inhibition seen with andexanet alfa

Cel-Sci and Ergomed sign deal for Multikine

Atterocor gains orphan drug status for ATR-101, initiates clinical program in ACC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...